During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics (NASDAQ:ARCT), revealing diverse outlooks from bullish to bearish. The following table summarizes their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback